28240640|t|Comparison of 270 Versus 320 mg I/mL of Iodixanol in 1 Image Assessment of Both Renal Arteries and Veins With Dual-Energy Spectral CT Imaging in Late Arterial Phase and Their Influence on Renal Function
28240640|a|The objective of this study was to compare the image quality of renal arteries and veins with dual-energy spectral computed tomography (CT) imaging in late arterial phase using 270 and 320 mg I/mL of iodixanol and their influence on renal function. A total of 1062 patients underwent renal CT angiography with 270 or 320 mg I/mL of iodixanol with dual-energy spectral CT imaging in late arterial phase. Image quality and their influence on renal function were compared. There were no significant differences of CT value, signal-to-noise ratio, contrast-to-noise ratio, and subjective score of renal vessels between 2 groups (all P > 0.05). The incidence of contrast-induced nephropathy in patients with abnormal renal function using 320 mg I/mL of iodixanol was significantly higher than using 270 mg I/mL of iodixanol (P = 0.043). The renal arteries and veins can be fully assessed in late arterial phase with 270 mg I/mL of iodixanol using dual-energy spectral CT scan with better preserved renal function.
28240640	0	10	Comparison	T052	C1707455
28240640	14	17	270	T200	C0977876
28240640	25	49	320 mg I/mL of Iodixanol	T200	C0977877
28240640	55	71	Image Assessment	T058	C4076410
28240640	80	94	Renal Arteries	T023	C0035065
28240640	99	104	Veins	T023	C0042449
28240640	110	141	Dual-Energy Spectral CT Imaging	T060	C0729619
28240640	145	164	Late Arterial Phase	T079	C0205390
28240640	175	184	Influence	T077	C4054723
28240640	188	202	Renal Function	T042	C0232804
28240640	225	230	study	T062	C2603343
28240640	238	245	compare	T052	C1707455
28240640	250	263	image quality	T080	C0806487
28240640	267	281	renal arteries	T023	C0035065
28240640	286	291	veins	T023	C0042449
28240640	297	350	dual-energy spectral computed tomography (CT) imaging	T060	C0729619
28240640	354	373	late arterial phase	T079	C0205390
28240640	380	383	270	T200	C0977876
28240640	388	412	320 mg I/mL of iodixanol	T200	C0977877
28240640	423	432	influence	T077	C4054723
28240640	436	450	renal function	T042	C0232804
28240640	468	476	patients	T101	C0030705
28240640	487	507	renal CT angiography	T060	C1637292
28240640	513	516	270	T200	C0977876
28240640	520	544	320 mg I/mL of iodixanol	T200	C0977877
28240640	550	581	dual-energy spectral CT imaging	T060	C0729619
28240640	585	604	late arterial phase	T079	C0205390
28240640	606	619	Image quality	T080	C0806487
28240640	630	639	influence	T077	C4054723
28240640	643	657	renal function	T042	C0232804
28240640	663	671	compared	T052	C1707455
28240640	714	722	CT value	T081	C1522609
28240640	724	745	signal-to-noise ratio	T081	C2986823
28240640	747	770	contrast-to-noise ratio	T081	C0456603
28240640	787	792	score	T081	C0449820
28240640	796	809	renal vessels	T023	C0580863
28240640	847	856	incidence	T081	C0021149
28240640	860	888	contrast-induced nephropathy	T047	C4055183
28240640	892	900	patients	T101	C0030705
28240640	906	929	abnormal renal function	T046	C0151746
28240640	936	960	320 mg I/mL of iodixanol	T200	C0977877
28240640	997	1021	270 mg I/mL of iodixanol	T200	C0977876
28240640	1039	1053	renal arteries	T023	C0035065
28240640	1058	1063	veins	T023	C0042449
28240640	1089	1108	late arterial phase	T079	C0205390
28240640	1114	1138	270 mg I/mL of iodixanol	T200	C0977876
28240640	1145	1173	dual-energy spectral CT scan	T060	C0177779
28240640	1196	1210	renal function	T042	C0232804